Park National Corp OH Sells 10,269 Shares of Abbott Laboratories $ABT

Key Points

• Park National Corp OH reduced its Abbott Laboratories stake by 6.8% in the third quarter, selling 10,269 shares and retaining 139,913 shares valued at approximately $13.8 million. Institutional investors collectively own 75.18% of Abbott stock.
• Abbott reported quarterly earnings of $1.31 per share on $12.59 billion in revenue, exceeding analyst estimates, while revenue increased 13% year over year. The company provided fiscal 2026 EPS guidance of $5.45 to $5.60.
• Abbott declared a quarterly dividend of $0.63 per share, representing an annualized dividend of $2.52 and a 2.5% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $119.80.

Park National Corp OH lessened its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 6.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,913 shares of the healthcare product maker's stock after selling 10,269 shares during the period. Park National Corp OH's holdings in Abbott Laboratories were worth $13,828,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. grew its stake in shares of Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock worth $13,843,610,000 after acquiring an additional 6,769,518 shares in the last quarter. State Street Corp grew its position in Abbott Laboratories by 1.7% in the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker's stock valued at $7,343,246,000 after purchasing an additional 1,350,766 shares in the last quarter. Capital International Investors lifted its position in Abbott Laboratories by 2.6% during the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker's stock worth $7,922,519,000 after buying an additional 1,614,706 shares in the last quarter. J. Stern & Co. LLP grew its holdings in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock valued at $4,926,279,000 after acquiring an additional 39,005,451 shares in the last quarter. Finally, Capital Research Global Investors increased its position in shares of Abbott Laboratories by 1.0% in the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker's stock valued at $4,907,523,000 after acquiring an additional 400,400 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Performance

Abbott Laboratories stock traded up $2.63 during mid-day trading on Monday, hitting $100.13. 3,498,474 shares of the company's stock traded hands, compared to its average volume of 11,315,676. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm has a 50 day simple moving average of $106.99 and a two-hundred day simple moving average of $98.60. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $135.24. The stock has a market cap of $173.27 billion, a price-to-earnings ratio of 32.45, a P/E/G ratio of 1.81 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company's quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories's payout ratio is currently 81.55%.

Analyst Ratings Changes

Several research analysts recently commented on ABT shares. JPMorgan Chase & Co. increased their price target on Abbott Laboratories from $110.00 to $120.00 and gave the company an "overweight" rating in a research report on Friday, July 17th. Robert W. Baird started coverage on Abbott Laboratories in a report on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 price objective for the company. Piper Sandler reissued an "overweight" rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. BTIG Research increased their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a research note on Friday, July 17th. Finally, Citigroup boosted their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a research note on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $119.80.

About Abbott Laboratories

Abbott Laboratories NYSE: ABT is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott's medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.